Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Intangibles (2016 - 2026)

Anika Therapeutics has reported Intangibles over the past 17 years, most recently at $1.7 million for Q1 2026.

  • Quarterly Intangibles changed 0.0% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, changed 0.0% year-over-year, with the annual reading at $1.6 million for FY2025, 91.68% down from the prior year.
  • Intangibles was $1.7 million for Q1 2026 at Anika Therapeutics, up from $1.6 million in the prior quarter.
  • Over five years, Intangibles peaked at $112.1 million in Q4 2022 and troughed at $600000.0 in Q3 2024.
  • The 5-year median for Intangibles is $49.9 million (2024), against an average of $44.0 million.
  • The largest YoY upside for Intangibles was 670.03% in 2024 against a maximum downside of 99.46% in 2024.
  • A 5-year view of Intangibles shows it stood at $112.1 million in 2022, then crashed by 97.7% to $2.6 million in 2023, then soared by 670.03% to $19.8 million in 2024, then crashed by 91.68% to $1.6 million in 2025, then rose by 3.03% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Intangibles are $1.7 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025).